European Lung Cancer Conference 2015

Oncology Meeting Resources

15 Apr - 18 Apr, Geneva, Switzerland

ELCC 2015

This multidisciplinary thoracic oncology conference aims to provide a regular update to all thoracic oncology specialists on different multidisciplinary topics important for research and clinical care in their practice, discuss critically the increasing understanding of biology of thoracic tumours and how it changes the diagnostic and treatment landscape, and present the latest advances in preclinical and clinical research in different settings across lung and other thoracic malignancies.

Abstracts, presentations and webcasts from the European Lung Cancer Conference (ELCC) 2015 are now available here. The use of these presentations is for personal educational purposes only. ESMO and IASLC thank the authors for their generosity.

Useful links

Presenter Presentation title Session title
Johan Vansteenkiste Welcome to the Conference Opening and Welcome
Rolf Stahel Introduction by the ESMO President Opening and Welcome
Tony Mok Introduction by the IASLC President Opening and Welcome
Rolf Stahel The development of oncological platforms across Europe The development of oncological platforms across Europe
Suresh Senan Stereotactic ablative RT after surgical treatment Local control after treatment of early stage lung cancer
Paul Van Schil Surgery after stereotactic ablative RT Local control after treatment of early stage lung cancer
David Jones Surgery for metachronous lung tumours Local control after treatment of early stage lung cancer
Solange Peters Checkpoint inhibitors: State of the art The evolving role of immunotherapy for lung cancer
Martin Reck Combination strategies The evolving role of immunotherapy for lung cancer
Johan Vansteenkiste Is there any room left for vaccines in lung cancer? The evolving role of immunotherapy for lung cancer
David Carbone Clinical trial design and perspectives The evolving role of immunotherapy for lung cancer
Giorgio Scagliotti Sequencing the mesothelioma genome in 2015 Mesothelioma: The rare disease that we need to know better
Umberto Ricardi Radiotherapist: A controversial role in this disease Mesothelioma: The rare disease that we need to know better
Paul Baas Systemic treatment: Old drugs or new approaches? Mesothelioma: The rare disease that we need to know better
Silvia Novello Other toxicities of targeted agents and their management Toxicity management of targeted agents